{
    "nct_id": "NCT04071366",
    "official_title": "A Phase 2 Study of Itacitinib, for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy",
    "inclusion_criteria": "* Part 1: Eligible to receive any IEC therapy for any approved indication.\n* Part 2: Eligible to receive Yescarta for relapsed or refractory large B-cell lymphoma or follicular lymphoma.\n* Eastern Cooperative Oncology Group performance status 0 to 1.\n* Willingness to avoid pregnancy or fathering children\nHealthy volunteers allowed\nMust have minimum age of 12 Years",
    "exclusion_criteria": "* Evidence of active uncontrolled/untreated infection (viral, bacterial, fungal, opportunistic) of any origin.\n* Evidence of active hepatitis B virus or hepatitis C virus infection.\n* Known human immunodeficiency virus.\n* Active acute or chronic graft-versus-host disease requiring systemic therapy.\n* Concurrent use of chronic systemic steroids or immunosuppressant medications.\n* Any unresolved toxicity â‰¥ Grade 2 (except stable Grade 2 peripheral neuropathy or alopecia) from previous anticancer therapy.\n* Known history or prior diagnosis of immunologic or inflammatory/autoimmune disease affecting the central nervous system (CNS) and unrelated to their disease under study or previous treatment.\n* Clinically significant or uncontrolled cardiac disease.\n* Acute lymphoblastic leukemia participants with protocol-defined CNS status are eligible only in the absence of neurologic symptoms suggestive of CNS leukemia.\n* Diffuse large B-cell lymphoma participants must have no signs or symptoms of CNS disease or detectable evidence of CNS disease; participants who have been previously treated for CNS disease but have no evidence of disease at screening are eligible.\n* Laboratory values at screening outside the protocol-defined ranges.",
    "miscellaneous_criteria": ""
}